Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors - Shimizu, Toshio; Powderly, John; Abdul Razak, Albiruni; LoRusso, Patricia; Miller, Kathy D.; Kao, Steven; Kongpachith, Sarah; Tribouley, Catherine; Graham, Michelle; Stoll, Brian; Patel, Maulik; Sahtout, Mohammad; et al. (Frontiers in Oncology, 2025)